The tyrosine kinase inhibitor nilotinib is more efficient than mitotane in decreasing cell viability in spheroids prepared from adrenocortical carcinoma cellsElaine R. Silveira, Claudimara Ferini Pacicco Lotfi|Cancer Cell International|2018Cited by 14